Last data update: Sep 16, 2024. (Total: 47680 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Johnson JC [original query] |
---|
Evaluation of the activity of lamivudine and zidovudine against Ebola virus
Cong Y , Dyall J , Hart BJ , DeWald LE , Johnson JC , Postnikova E , Zhou H , Gross R , Rojas O , Alexander I , Josleyn N , Zhang T , Michelotti J , Janosko K , Glass PJ , Flint M , McMullan LK , Spiropoulou CF , Mierzwa T , Guha R , Shinn P , Michael S , Klumpp-Thomas C , McKnight C , Thomas C , Eakin AE , O'Loughlin KG , Green CE , Catz P , Mirsalis JC , Honko AN , Olinger GG Jr , Bennett RS , Holbrook MR , Hensley LE , Jahrling PB . PLoS One 2016 11 (11) e0166318 In the fall of 2014, an international news agency reported that patients suffering from Ebola virus disease (EVD) in Liberia were treated successfully with lamivudine, an antiviral drug used to treat human immunodeficiency virus-1 and hepatitis B virus infections. According to the report, 13 out of 15 patients treated with lamivudine survived and were declared free from Ebola virus disease. In this study, the anti-Ebola virus (EBOV) activity of lamivudine and another antiretroviral, zidovudine, were evaluated in a diverse set of cell lines against two variants of wild-type EBOV. Variable assay parameters were assessed to include different multiplicities of infection, lengths of inoculation times, and durations of dosing. At a multiplicity of infection of 1, lamivudine and zidovudine had no effect on EBOV propagation in Vero E6, Hep G2, or HeLa cells, or in primary human monocyte-derived macrophages. At a multiplicity of infection of 0.1, zidovudine demonstrated limited anti-EBOV activity in Huh 7 cells. Under certain conditions, lamivudine had low anti-EBOV activity at the maximum concentration tested (320 muM). However, lamivudine never achieved greater than 30% viral inhibition, and the activity was not consistently reproducible. Combination of lamivudine and zidovudine showed no synergistic antiviral activity. Independently, a set of in vitro experiments testing lamivudine and zidovudine for antiviral activity against an Ebola-enhanced green fluorescent protein reporter virus was performed at the Centers for Disease Control and Prevention. No antiviral activity was observed for either compound. A study evaluating the efficacy of lamivudine in a guinea pig model of EVD found no survival benefit. This lack of benefit was observed despite plasma lamivudine concentrations in guinea pig of about 4 mug/ml obtained in a separately conducted pharmacokinetics study. These studies found no evidence to support the therapeutic use of lamivudine for the treatment of EVD. |
Volumetric measurement of rock movement using photogrammetry
Benton DJ , Iverson SR , Martin LA , Johnson JC , Raffaldi MJ . Int J Min Sci Technol 2015 26 (1) 123-130 NIOSH ground control safety research program at Spokane, Washington, is exploring applications of photogrammetry to rock mass and support monitoring. This paper describes two ways photogrammetric techniques are being used. First, photogrammetric data of laboratory testing is being used to correlate energy input and support deformation. This information can be used to infer remaining support toughness after ground deformation events. This technique is also demonstrated in a field application. Second, field photogrammetric data is compared to crackmeter data from a deep underground mine. Accuracies were found to average 8. mm, but have produced results within 0.2. mm of true displacement, as measured by crackmeters. Application of these techniques consists of monitoring overall fault activity by monitoring multiple points around the crackmeter. A case study is provided in which a crackmeter is clearly shown to have provided insufficient information regarding overall fault ground deformation. Photogrammetry is proving to be a useful ground monitoring tool due to its unobtrusiveness and ease of use. |
Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.
Kuhn JH , Andersen KG , Bao Y , Bavari S , Becker S , Bennett RS , Bergman NH , Blinkova O , Bradfute S , Brister JR , Bukreyev A , Chandran K , Chepurnov AA , Davey RA , Dietzgen RG , Doggett NA , Dolnik O , Dye JM , Enterlein S , Fenimore PW , Formenty P , Freiberg AN , Garry RF , Garza NL , Gire SK , Gonzalez JP , Griffiths A , Happi CT , Hensley LE , Herbert AS , Hevey MC , Hoenen T , Honko AN , Ignatyev GM , Jahrling PB , Johnson JC , Johnson KM , Kindrachuk J , Klenk HD , Kobinger G , Kochel TJ , Lackemeyer MG , Leroy EM , Lever MS , Muhlberger E , Netesov SV , Olinger GG , Omilabu SA , Palacios G , Panchal RG , Park DJ , Patterson JL , Paweska JT , Peters CJ , Pettitt J , Pitt L , Radoshitzky SR , Ryabchikova EI , Saphire EO , Sabeti PC , Sealfon R , Smither SJ , Sullivan NJ , Swanepoel R , Takada A , Towner JS , van der Groen G , Volchkov VE , Volchkova VA , Wahl-Jensen V , Warren TK , Warfield KL , Weidmann M , Nichol ST . Viruses 2014 6 (9) 3663-82 Sequence determination of complete or coding-complete genomes of viruses is becoming common practice for supporting the work of epidemiologists, ecologists, virologists, and taxonomists. Sequencing duration and costs are rapidly decreasing, sequencing hardware is under modification for use by non-experts, and software is constantly being improved to simplify sequence data management and analysis. Thus, analysis of virus disease outbreaks on the molecular level is now feasible, including characterization of the evolution of individual virus populations in single patients over time. The increasing accumulation of sequencing data creates a management problem for the curators of commonly used sequence databases and an entry retrieval problem for end users. Therefore, utilizing the data to their fullest potential will require setting nomenclature and annotation standards for virus isolates and associated genomic sequences. The National Center for Biotechnology Information's (NCBI's) RefSeq is a non-redundant, curated database for reference (or type) nucleotide sequence records that supplies source data to numerous other databases. Building on recently proposed templates for filovirus variant naming [<virus name> (<strain>)/<isolation host-suffix>/<country of sampling>/<year of sampling>/<genetic variant designation>-<isolate designation>], we report consensus decisions from a majority of past and currently active filovirus experts on the eight filovirus type variants and isolates to be represented in RefSeq, their final designations, and their associated sequences. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Sep 16, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure